News & Perspective

Sep 26, 2008

Sep 26, 2008

Emergent garners $29 million for new anthrax vaccine

(CIDRAP News) – Emergent BioSolutions announced today that it has received a $29.7 million contract from the federal government to continue work on another of its next-generation anthrax vaccine candidates.

Sep 09, 2008

Sep 09, 2008

HHS funds work on new anthrax antitoxin

(CIDRAP News) – Emergent BioSolutions Inc. recently announced that it won a federal contract worth $24.3 million to develop a monoclonal antibody treatment to block the effects of anthrax toxin.

Aug 26, 2008

Aug 26, 2008

Anthrax probe prompts concerns about military labs

(CIDRAP News) –US Navy and Air Force officials recently reported a suspension of work in their biodefense laboratories to allow a thorough review of safety procedures, following the Army's announcement in early August that it would review security measures at the lab that housed the work of the late Bruce E. Ivins, whom federal officials believe played a role in the 2001 anthrax attacks.

Jul 29, 2008

Jul 29, 2008

Anthrax vaccine maker wins NIAID grants

(CIDRAP News) – Emergent BioSolutions Inc. recently announced it had secured two federal grants totaling $4.5 million for development of its botulism and next-generation anthrax vaccine candidates.

Emergent, maker of the nation's only licensed anthrax vaccine, announced the grants from the National Institute of Allergy and Infectious Diseases (NIAID) in a Jul 24 news release.

May 02, 2008

May 02, 2008

Researchers find fast way to make human antibodies against flu

(CIDRAP News) – Technical barriers have prevented the widespread use of human monoclonal antibodies as potent diagnostic and treatment tools, but scientists now say they have found a way to produce antibodies against seasonal influenza much faster than was previously possible.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»